PMV Pharmaceuticals, Inc. (PMVP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
8 Clarke Drive
Princeton, NJ 08512
United States of America (the)
Phone
609 642 6670
Website
Sector
Healthcare
Industry
Biotechnology
Employees
47
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| David H. Mack | Co-Founder, Chief Executive Officer, President & Director | 912,871 | 1962 |
| Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board | 140,000 | 1940 |
| Michael Carulli | Chief Financial Officer | 532,801 | 1974 |
| Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary | 612,000 | 1962 |
| Deepika Jalota | Chief Development Officer | 653,067 | 1977 |
| Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations | 0 | N/A |
| Laura De Leon | VP & Head of Clinical Development Operations | 0 | N/A |
| Binh Vu | Senior Vice President of Drug Discovery & CMC | 0 | N/A |
| Marc Fellous | Senior Vice President and Head of Clinical Development & Medical Affairs | 0 | N/A |
| Crystal Zuckerman | Vice President of Human Resources | 0 | N/A |
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.